What Chicago Biomedical Consortium does

The Chicago Biomedical Consortium (CBC) is a nonprofit research consortium founded in 2006 to accelerate the translation of academic biomedical discoveries into investable innovations and to build the Midwest biotech ecosystem. It operates across nine universities in Illinois, anchored by three founding institutions — The University of Chicago, Northwestern University, and University of Illinois Chicago — and delivers a portfolio of grant programs (Accelerator Award, Catalyst Award, COVID-19 Response Award, CBCAN), an Entrepreneurial Fellows program, CBC-HITES (a health information technology extension service), a Core Facilities Directory, Small Molecule Discovery resources, and educational seminars and workshops.

CBC's core operating model is its "Greenhouse" approach, which deploys patient capital and resources into the pre-company, unprofitable stages of biomedical translation — replication studies, target validation, fit-for-purpose models, and IND-enabling plans — where traditional venture capital does not yet participate. The underlying technology is essentially an operating and funding methodology paired with shared research infrastructure (proteomics, informatics, high-throughput screening) across member institutions, rather than a packaged product or software platform. The stated intent is to build a self-reinforcing ecosystem in which discoveries become investable ventures, ventures create skilled jobs, and those jobs anchor Illinois as a credible life-sciences hub.

Revenue mechanics are nonprofit and non-commercial: CBC is funded through foundation grants, philanthropy, and federal sources such as NIH, with the Walder Foundation highlighted as a key financial partner. Services are delivered via direct institutional collaboration with member universities rather than through pricing or commercial sales channels. Leadership includes Executive Director Michelle Burbea Hoffmann and Scientific Directors Shohei Koide and Brian Kay. The organization's customers are academic researchers and institutions in Illinois whose early-stage biomedical projects receive funding, expertise, and access to consortium-level resources.

Name

Chicago Biomedical Consortium

Legal name

Chicago Biomedical Consortium

Website

https://chicagobiomedicalconsortium.org

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

The Chicago Biomedical Consortium (CBC) is a 2006-founded nonprofit that funds early-stage translational biomedical research across nine Illinois universities, using a Greenhouse model with patient capital to convert academic discoveries into investable ventures and train translational operators.

Ownership category

akta.pro rank

Product category

Biomedical Research Funding Consortium

NAICS

Grantmaking Foundations (813211), Voluntary Health Organizations (813212), Scientific Research and Development Services (5417), Grantmaking and Giving Services (81321)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

Research & Science Grantmaking Foundations (BPAGAKAI), Health Research Funding Agencies (Public/Quasi-Public) (HLAJALAB), Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

Keywords

• Biomedical research funding
• Translational research support
• Nonprofit research consortium
• Biotech ecosystem development
• Academic science grants

Headquarters

HQ city

Evanston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Grant funding and philanthropy: The CBC operates as a nonprofit consortium funded through grants and charitable donations. It applies venture-level rigor and patient capital at the academic level before companies exist to transform scientific discoveries into investable ideas.

Distribution channels1 record

Marketing channels5 records

Core offering

The Chicago Biomedical Consortium is a nonprofit research consortium that funds and supports early-stage translational biomedical research across nine Illinois universities. It provides grant awards (Catalyst Award, Accelerator Award, COVID-19 Response Award), the Entrepreneurial Fellows program, CBCAN, CBC-HITES, shared Core Facilities, and educational programming, all delivered through a proprietary Greenhouse model that applies patient capital at the academic level before investable companies exist.

Product overview

The Chicago Biomedical Consortium (CBC) is a regional life-sciences consortium that operates as a funding and ecosystem development organization rather than a product company. Its offerings consist of grant programs (Catalyst Award, Accelerator Award, COVID-19 Response Award), the Entrepreneurial Fellows program, CBC-HITES (a health information technology extension service), a Core Facilities Directory, Small Molecule Discovery resources, and educational programming including seminars and workshops. These are organizational programs and services, not packaged software products.

Differentiator

Problem solved

Functional benefit

Products and services

• Catalyst Award Grant program from the Chicago Biomedical Consortium supporting early-stage translational biomedical research at Illinois universities; provides resources for replication studies, target validation, and other pre-venture work where venture capital cannot yet go.
• Accelerator Award Grant program supporting translational biomedical research projects at Illinois universities, intended to advance discoveries toward investable ventures.
• COVID-19 Response Award Grant program funding biomedical research projects related to the COVID-19 response at Illinois universities.
• Entrepreneurial Fellows Program Fellowship program that trains and places a new generation of translational operators in the Chicago biotech ecosystem, supported by partners including the Walder Foundation.
• CBCAN CBC program supporting translational biomedical research activities across the Chicago Biomedical Consortium network.
• CBC-HITES CBC-HITES is a health information technology extension service offered through the Chicago Biomedical Consortium.
• Core Facilities Directory Directory of shared research facilities across the CBC member institutions, providing access to proteomics, informatics, and high-throughput screening capabilities for translational biomedical research.
• Small Molecule Discovery Resources Research resources supporting small molecule discovery for translational biomedical projects within the CBC network.
• CBC Summit (BioCapital Summit) Industry conference organized by the CBC, including BioCentury's Grand Rounds and the Biocapital Summit, convening biotech and translational stakeholders across the Midwest.

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and strategic.

• The University of ChicagocoreStrategic or Co-development PartnerMember institution of the Chicago Biomedical Consortium. One of the three core university partners providing research expertise and infrastructure for translational biomedical research programs including proteomics, high-throughput screening, and seminars.
• Northwestern UniversitycoreStrategic or Co-development PartnerMember institution of the Chicago Biomedical Consortium. One of the three core university partners contributing to collaborative research programs, proteomics facilities, and the Entrepreneurial Fellows program.
• University of Illinois ChicagocoreStrategic or Co-development PartnerMember institution of the Chicago Biomedical Consortium. One of the three core university partners hosting core facilities including the Proteomics and Informatics Services Facility for the consortium.
• P33 ChicagostrategicStrategic or Co-development PartnerP33 Chicago's SVP of Deep Tech Meera Raja joined BioCentury podcast preview with CBC Executive Director Michelle Hoffmann for Grand Rounds conference collaboration.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Others

• FasterCures (Milken Institute): Nonprofit center that works across philanthropic, academic, and industry actors to accelerate biomedical innovation from lab to patient. Adjacent to CBC's translational mission but operates at a national advocacy and convening level rather than as a regional grantmaker.
• Health Research Alliance: National nonprofit consortium of private and nonprofit health research funders that share data, evaluate outcomes, and coordinate grantmaking practices. Adjacent to CBC as a peer consortium of biomedical research funders rather than a direct competitor.

Direct peers

• Indiana Biosciences Research Institute: Indianapolis-based nonprofit research institute that collaborates with Midwestern universities and industry on translational life sciences projects. Comparable as a regional bioscience translational intermediary anchored to multiple institutional partners.
• New York Genome Center: New York-based nonprofit research consortium uniting academic, medical, and industry partners for large-scale genomic and biomedical research. Comparable as a multi-institutional biomedical consortium with shared core resources.
• BioGenerator: St. Louis-based nonprofit that provides patient capital, lab space, and company-formation support to academic and local biotech founders. Operates the same venture-creation model in a different Midwestern region, making it a close functional analog to CBC's Greenhouse model.
• QB3 (California Institute for Quantitative Biosciences): University of California multi-campus institute that connects academic biomedical researchers with entrepreneurship and industry partners. Comparable as a multi-university biomedical consortium focused on translating academic science into ventures.
• California Institute for Regenerative Medicine (CIRM): State-funded agency that makes grants and loans for stem cell and related biomedical research at California institutions. Mirrors CBC's grantmaking role at a much larger scale and provides a reference point for how a state-anchored biomedical funding intermediary is structured.
• BioAccel: Arizona-based nonprofit biomedical accelerator that funds and mentors translational projects toward commercialization. Mirrors CBC's mission of bridging the funding gap between academic discovery and venture-ready biotech.

Broad incumbents

• Massachusetts Life Sciences Center: Quasi-public state agency that invests in life sciences research, infrastructure, and workforce development across Massachusetts. Sits at a much larger scale than CBC but provides a useful analog for how state-anchored life sciences intermediaries are designed.

Emerging players

• Philadelphia Science Center / University City Science Center: Nonprofit research park and entrepreneurship hub connecting Philadelphia-area universities and life sciences startups. Comparable as a multi-university translational intermediary focused on building a regional life sciences cluster.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CBC_ChiBiomed
• Facebookfacebook.com/sharer/sharer.php?u=https%3A%2F%2Fchicagobiomedicalconsortium.org%2F
• LinkedInlinkedin.com/company/chibiomed

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chicago Biomedical Consortium